SEPAPY A BY GIBS FORM PTO-1449 (Modified) ATTY. DOCKET NO.: V0179/7001 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S APPLICANT: Wanker et al. INFORMATION DISCLOSURE STATEMENT FILING DATE: Herewith GROUP: Not yet assigned **U.S. PATENT DOCUMENTS** Exam Ref Sub FILING DATE Date Init Des Document No. Name Class Class If Appropriate 5,234,814 08/10/93 Card et al. 7.21 435 06/01/89 5,723,301 03/03/98 Burke et al. 435 7.1 11/03/95 **FOREIGN PATENT DOCUMENTS** Country & Pub Sub Translation Doc. No. (11) Date (43) Class Class Yes EP 0 206302A2 -30.12.86 EP 0 293 249 A1 30.11.88 EP 0 854 364 A1 22.07.98 WO95/29243 02.11.95 WO96/12544 02.05.96 WO96/28471 19.09.96 WO97/17445 -15.05.97 **OTHER ART** (Including Author, Title, Date, Pertinent Pages, Publication, Etc.) Kisilevsky et al., "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease", (2/95), pp. 143-148, Nature Medicine, Vol. 1, No. 2. Trottler et al., "Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias", (11/23/85), pp. 403-406, Nature Vol. 378. Gutekunst et al., "Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies", (9/95), pp. 8710-8714, Pro. Natl. Acad. Sci. USA Vol. 92 Neurobiology. M.F. Perutz, "Glutamine repeats and inherited neurodegenerative diseases: molecular aspects", (1996) pp. 848-919 858, MRC Laboratory of Molecular Biology. EXAMINER DATE CONSIDERED priline 10/24/01 EXAMINER: Initial if reference considered, whether or not citation is in conformance with

MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant



FORM PTO-1449(Modified)	ATTY. DOCKET NO.: V0179/7001	SEPPOND INS EN PORT
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Wanker et al.	
	FILING DATE: Herewith	GROUP: Not yet assigned

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

	(morating retailer, Tale, Date, Tellificial Tages, Tublication, Ltc.)		
94	Mangiarini et al., "Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive		
	neurological phenotype in transgenic mice", (11/01/96), pp. 493-506, Cell, Vol. 87.		
99	Stott et al., "Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative		
	diseases", (7/95), pp. 6509-6513, Pro. Natl. Acad. Sci. USA, Vol. 92, Biochemistry.		
gry	Merlini et al., "Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with anyloid fibrils: Inhibition of		
	amyloidogenesis", (3/95), pp. 2959-2963, Proc. Natl. Acad. Sci. USA, Vol. 92, Medical Sciences.		
gry	Scherzinger, et al., "Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in		
	vitro and in vivo", (8/8/97), pp. 549-558, Cell, Vol. 90.		
	Davies et al., "Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice		
	transgenic for the HD mutation", (8/8/97), pp. 537-548, Cell, Vol. 90.		
gry Derv	Derwent, "Nucleic acid fragments associated with spinocerebellar ataxis type 2-contain increased number of		
	CAG repeat region compared to normal gene", (5/7/98), XP-002101183. Abstract		
grs	Tateishe et al., "Removal of causative agent of creutzefeldt-jakob disease (CJD) through membrane filtration method",		
	(1993), pp. 357-362, Membrane, 18(6).		

EXAMINER

Brilen B. Bakel

DATE CONSIDERED /6/

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant